Clinical Trial
Study Details
Low dose arm
150 mg Loading Dose; 10 mg daily dose
Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease (SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs) that blocks RBC dehydration. ICA-17043 is expected to inhibit RBC dehydration and thus should prevent or delay the sickling process. By reducing sickled cells, an improvement in anemia, a reduction in painful crises, and ultimately, less end-organ disease is anticipated.
Study Overview
Contacts and Locations
Study Site
Birmingham, Alabama
United States
Study Site
Oakland, California
United States
Study Site
San Francisco, California
United States
Study Site
Washington D.C., District of Columbia
United States
Study Site
Augusta, Georgia
United States
Study Site
Chicago, Illinois
United States
Study Site
Baltimore, Maryland
United States
Study Site
Boston, Massachusetts
United States
Study Site
Detroit, Michigan
United States
Study Site
Jackson, Mississippi
United States
Study Site
Brooklyn, New York
United States
Study Site
New York, New York
United States
Study Site
Chapel Hill, North Carolina
United States
Study Site
Durham, North Carolina
United States
Study Site
Philadelphia, Pennsylvania
United States
Study Site
Pittsburgh, Pennsylvania
United States
Study Site
Nashville, Tennessee
United States
Study Site
Houston, Texas
United States
Study Site
Richmond, Virginia
United States